Published by Global Banking & Finance Review®
Posted on May 12, 2025
1 min readLast updated: January 23, 2026
Add as preferred source on GoogleGrifols's net profit tripled in Q1, boosting confidence in its 2025 outlook. Revenue and EBITDA also saw significant growth.
(This story has been corrected to fix the spelling of the company name in the headline, and to add a dropped word 'to,' in paragraph 3)
MADRID (Reuters) -Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
Reported group profit grew by 179% in the first three months of the year to 60 million euros ($66.41 million) while adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) grew 14.2% to 400 million euros, Grifols said in a statement on Monday.
Net revenue rose 7.4% to 1.79 billion euros in the first quarter thanks to a strong performance from its plasma-derived medicine business.
($1 = 0.9035 euros)
(Reporting by Charlie Devereux; editing by Inti Landauro)
The article discusses Grifols's significant profit increase and its confidence in meeting its 2025 financial outlook.
Grifols's net profit increased by 179% in the first quarter compared to the previous year.
The revenue growth was driven by a strong performance in its plasma-derived medicine business.
Explore more articles in the Finance category
